Reacción #1726709

ord-764a21ddb1184ccebf879e23a3e47f8b

Ecuación de reacción

O=C1CCNCC1
4-piperidone
CC(=O)Nc1ccc(O)c(C(N)=O)c1
5-acetamido-2-hydroxybenzamide
C1COCCN1
morpholine
O=C1NC2(CCNCC2)Oc2ccccc21
Compound 9
O=C1NC2(CCNCC2)Oc2ccccc21
spiro[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one

Condiciones de reacción

Condiciones detalladas
See reaction.notes.procedure_details.

Tratamiento posterior

  1. 1
    Temperaturais refluxed for 48 hr
  2. 2
    Lavadowashed with water, brine
  3. 3
    Secadodried over Na2SO4
  4. 4
    OtroAfter solvent removal by rotoevaporation
  5. 5
    Otrothe crude product is purified by preparative TLC

Procedimiento

A mixture of 24 mg (0.077 mmol) of N-[4,8-dimethoxyquinoline-2-yl)carbonyl]-4-piperidone, 15 mg (0.077 mmol) of 5-acetamido-2-hydroxybenzamide, and 0.020 mL of morpholine in 3 mL of methanol is refluxed for 48 hr. The reaction mixture is diluted with ethyl acetate, and washed with water, brine, and dried over Na2SO4. After solvent removal by rotoevaporation, the crude product is purified by preparative TLC to give 11 mg (0.022 mmol, 30% yield) of 6-acetamido-1′-[4,8-dimethoxyquinoline-2-yl)carbonyl]spiro[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one (Compound 9): 1H NMR (DMSO-d6): δ 2.02 (s, 3H), 3.95 (s, 3H), 4.06 (s, 3H), 7.03 (d, 1H), 8.19 (s, 1H), 7.24 (d of d, 1H), 7.52 (d of d, 1H), 7.67 (m, 2H), 8.02 (d, 1H), 8.82, (s, 1H) and 9.98 ppm (s, 1H). MS m/z: 491.1 (M+H)+, 513.2 (M+Na)+.

Fuente

DOI: 10.6084/m9.figshare.5104873.v1Patente: US08110570B2uspto-grants-2012_02